Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €46.26 EUR
Change Today +0.305 / 0.66%
Volume 0.0
EC8 On Other Exchanges
Symbol
Exchange
Berlin
As of 2:20 AM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

conmed corp (EC8) Snapshot

Open
€46.22
Previous Close
€45.95
Day High
€46.26
Day Low
€46.22
52 Week High
07/21/15 - €55.01
52 Week Low
09/26/14 - €28.56
Market Cap
1.3B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
27.7M
EX-Date
09/11/15
P/E TM
--
Dividend
€0.80
Dividend Yield
1.46%
Current Stock Chart for CONMED CORP (EC8)

conmed corp (EC8) Related Bloomberg News

View More Bloomberg News

conmed corp (EC8) Related Businessweek News

No Related Businessweek News Found

conmed corp (EC8) Details

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures and monitoring in the United States, Canada, the United Kingdom, Japan, Australia, and internationally. The company offers sports medicine products, such as powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bio absorbable implants, and related disposable products and fluid management systems; powered surgical instruments for use in large and small bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; and sports biologics and tissues. It also provides electrosurgical generators, hand pieces, smoke management systems, and accessories for surgical needs; and endomechanical instrumentation products that offer various instruments comprising trocars, clip appliers, scissors, and surgical staplers used in the minimally invasive laparoscopic and gynecological surgery, as well as an uterine manipulator for use in the laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, the company provides mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and polypectomy; pulse oximetry equipment and sensors, ECG electrodes and cables, cardiac defibrillation and pacing pads, and blood pressure cuffs; suction instruments and tubing for use in the operating room; IV products for use in the critical care areas of the hospital; pulmonary monitoring products; and imaging systems for use in the minimally invasive orthopedic and general surgery procedures. The company’s products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

3,500 Employees
Last Reported Date: 02/23/15
Founded in 1970

conmed corp (EC8) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $262.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $328.7K
Executive Vice President of Legal Affairs and...
Total Annual Compensation: $299.0K
Compensation as of Fiscal Year 2014.

conmed corp (EC8) Key Developments

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2015

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2015 to all shareholders of record as of September 15, 2015.

CONMED Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reiterates Earnings Guidance for the Year 2015

CONMED Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of $181,027,000 against $188,150,000 a year ago. Income from operations was $12,416,000 against $15,940,000 a year ago. Income before income taxes was $10,927,000 against $14,369,000 a year ago. Net income was $7,461,000 or $0.27 per basic and diluted share against $10,255,000 or $0.37 per diluted share a year ago. EBITDA was $23,178,000 against $27,231,000 a year ago. Adjusted EBITDA was $28,778,000 against $32,761,000 a year ago. For the six months, the company reported net sales of $358,967,000 against $370,091,000 a year ago. Income from operations was $23,370,000 against $33,248,000 a year ago. Income before income taxes was $20,421,000 against $30,216,000 a year ago. Net income was $13,773,000 or $0.49 per diluted share against $18,881,000 or $0.68 per diluted share a year ago. Net cash provided by operating activities was $25,055,000 against $24,913,000 a year ago. Purchases of property, plant, and equipment were $6,104,000. EBITDA was $44,155,000 against $55,260,000 a year ago. Adjusted EBITDA was $59,520,000 against $66,120,000 a year ago. The company reiterated its previously disclosed constant currency sales guidance, which calls for organic sales growth in 2015 to be in the range of 1% to 3%. Using current exchange rates, CONMED continues to anticipate that reported sales for 2015 will be in the range of $723 million to $738 million, representing a growth range of (2%) to 0%, and that adjusted diluted net earnings per share will be in the range of $1.82 to $1.92.

CONMED Corporation Appoints David Bronson and John L. Workmanto to its Board of Directors

CONMED Corporation announced that it has added David Bronson and John L. Workmanto its Board of Directors, effective immediately. Mr. Bronson served as Executive Vice President and Chief Financial Officer of PSS World Medical Inc. from 2002 until it was acquired by McKesson Corp. in 2013. Mr. Workman served as Chief Executive Officer of Omnicare Inc. from 2012 to 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EC8:GR €46.26 EUR +0.305

EC8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Integra LifeSciences Holdings Corp $60.54 USD +0.83
Masimo Corp $42.14 USD +1.29
NuVasive Inc $52.75 USD +1.03
Paramount Bed Holdings Co Ltd ¥3,595 JPY -10.00
Wright Medical Group Inc $23.43 USD -0.05
View Industry Companies
 

Industry Analysis

EC8

Industry Average

Valuation EC8 Industry Range
Price/Earnings 54.5x
Price/Sales 2.0x
Price/Book 2.5x
Price/Cash Flow 54.3x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONMED CORP, please visit www.conmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.